Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2021, Vol. 48 Issue (2): 257-262    DOI: 10.31083/j.ceog.2021.02.2364
Original Research Previous articles | Next articles
Pregnancy and neonatal outcomes of hyperglycemia caused by atosiban administration during pregnancy
Hyun Jin Ko1, †, Seong Yeon Hong1, †, Jin Young Bae1, *, ()
1Department of Obstetrics and Gynecology, Catholic University of Daegu, School of Medicine, 42472 Daegu, Korea
Download:  PDF(429KB)  ( 130 ) Full text   ( 20 )
Export:  BibTeX | EndNote (RIS)      
It is known that atosiban has fewer side effects than conventional tocolytics. In clinical practice, however, hyperglycemia can be commonly observed in mothers who have been administered atosiban. Therefore, we investigated whether intravenous atosiban injection actually causes hyperglycemia and how these changes affect newborns. From December 2015 to July 2018, a retrospective study was conducted on 96 mothers who were diagnosed with preterm labor and were administered atosiban at our institution. Maternal blood glucose was measured and compared before and during the administration of atosiban. The paired t-test, independent samples t-test, Chi-square test and Fisher's exact test were performed using SPSS version 21.0. A statistically significant increase in fasting blood glucose levels was observed during the administration of atosiban, compared with random blood glucose levels before administration (110.7 mg/dL vs. 86.3 mg/dL). The mean postprandial blood glucose level during administration was 170.75 mg/dL. Gestational diabetes, twin pregnancy, preeclampsia, and polyhydramnios did not significantly affect the degree of blood glucose increase. Statistically significant hypoglycemia was observed after performing a neonatal blood test immediately after birth from mothers who used atosiban. The neonates from the group with elevated maternal blood glucose levels exceeding 20 mg/dL showed lower blood glucose levels. No serious side effects other than hypoglycemia were observed. Atosiban administration in pregnant women results in significantly elevated maternal blood glucose, which results in hypoglycemia in neonates after birth. Therefore, neonates from mothers who received atosiban require a blood glucose test and close monitoring after birth.
Key words:  Atosiban      Preterm labor      Maternal hyperglycemia      Neonatal hypoglycemia     
Submitted:  16 November 2020      Revised:  13 December 2020      Accepted:  31 December 2020      Published:  15 April 2021     
*Corresponding Author(s):  Jin Young Bae     E-mail:
About author:  These authors contributed equally.

Cite this article: 

Hyun Jin Ko, Seong Yeon Hong, Jin Young Bae. Pregnancy and neonatal outcomes of hyperglycemia caused by atosiban administration during pregnancy. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 257-262.

URL:     OR

[1] Kumari Anukriti, Kiran Guleria, Vipin Tyagi, Amita Suneja, B D Banerjee. Maternal blood and amnionic oxytocin receptor gene expression and serum oxytocin levels in preterm birth: a case-control study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 283-291.
[2] S. Han, S. Choi, S. Nah, Y.H. Lee. Preterm labor in mild carbon monoxide poisoning: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 805-806.
[3] S.A. Hebisha, Hisham M. Adel. Impact of the oxytocin receptor antagonist atosiban administered shortly before embryo transfer on pregnancy rates after ICSI[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 513-516.
[4] Kwan Young Oh, Chan Hee Jin, Yong Hak Sohn, Hyun A. Cho, Moran Ki. The prevalence of abnormal vaginal flora and predictive factors for intrauterine infection in pregnant Korean women with preterm labor[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(3): 429-433.
[5] F.Y. Azizieh, R. Raghupathy. IL-10 and pregnancy complications[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(2): 252-258.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] Sandeep K. Krishnan, Norman E. Lepor. Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management[J]. Reviews in Cardiovascular Medicine, 2016, 17(S1): 9 -21 .
[3] Ibrahim Sidiqi, Patrick Alexander. Current Advances in Endovascular Therapy for Infrapopliteal Artery Disease[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 36 -50 .
[4] Peter Shalit. Management of Dyslipidemia in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 38 -46 .
[5] Sophie Mavrogeni, Fabrizio Cantini, Gerald M. Pohost. Systemic Vasculitis: An Underestimated Cause of Heart Failure—Assessment by Cardiovascular Magnetic Resonance[J]. Reviews in Cardiovascular Medicine, 2013, 14(1): 49 -55 .
[6] Prabhjot Singh Nijjar, Anoop Parameswaran, Aman M. Amanullah. Evaluation of Anomalous Aortic Origins of the Coronaries by 64-Slice Cardiac Computed Tomography[J]. Reviews in Cardiovascular Medicine, 2007, 8(3): 175 -181 .
[7] Jeffrey W. Moses, Stephane Carlier, Issam Moussa. Lesion Preparation Prior to Stenting[J]. Reviews in Cardiovascular Medicine, 2004, 5(S2): 16 -21 .
[8] Dean J. Kereiakes. Coronary Small-Vessel Stenting in the Era of Drug Elution[J]. Reviews in Cardiovascular Medicine, 2004, 5(S2): 34 -45 .
[9] Steven V. Edelman. The Role of the Thiazolidinediones in the Practical Management of Patients With Type 2 Diabetes and Cardiovascular Risk Factors[J]. Reviews in Cardiovascular Medicine, 2003, 4(S6): 29 -37 .
[10] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .